ASTRAZENECA PLC (AZN)
About ASTRAZENECA PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Market cap
- $262.5B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $262.5B
- Dividend yield
- 0.97%
- Shares outstanding
- 1.6B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 23, 2009
Astrazeneca PLC (AZN) Stock Price
- Trading 21% below its 52-week high.
- Pays a dividend yielding about 0.97% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ASTRAZENECA PLC.
Write a review
News about ASTRAZENECA PLC
News & sentiment via Polygon.io
Astrazeneca PLC: frequently asked questions
Is Astrazeneca PLC an American company?
Astrazeneca PLC is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Astrazeneca PLC publicly traded?
Yes — Astrazeneca PLC is a publicly traded company. Its stock trades under the ticker symbol AZN on the NYSE.
What does Astrazeneca PLC do?
Astrazeneca PLC is an American Pharmaceuticals company in the Health & Beauty sector.
When was Astrazeneca PLC founded?
Astrazeneca PLC was founded in 1913.
